Business
Alpha Tau to Host Conference Call to Discuss Interim Results from First Three Patients Treated for Recurrent Glioblastoma
JERUSALEM, May 08, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) ("Alpha Tau", or the “Company”), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT® today announced that it will host a conference call and webcast on Monday, May 11, 2026 at 8:30am ET to discuss interim clinical data from the first three patients treated in its U.S. trial of Alpha DaRT for patients with recurrent glioblastoma (GBM), also known as the REGAIN (Recurrent Glioblastoma Al
About this update from Alpha Tau Medical Ltd.
[{"type":"image","alt":"Alpha Tau Medical Ltd.","displaySize":"","headline":null,"caption":"Alpha Tau Medical Ltd.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":215,"url":"https://media.zenfs.com/en/globenewswire.com/05605e0853ddac4177652b0fbd0afb40"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/7VgHu6alli3.BtV2lI3Eng--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTMwMQ--/https://media.zenfs.com/en/globenewswire.com/05605e0853ddac4177652b0fbd0afb40","width":300,"height":215},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/7VgHu6alli3.BtV2lI3Eng--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTMwMQ--/https://media.zenfs.com/en/globenewswire.com/05605e0853ddac4177652b0fbd0afb40","width":300,"height":215}},"lazy":false},{"type":"text","content":"JERUSALEM, May 08, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) ("Alpha Tau", or the “Company”), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT® today announced that it will host a conference call and webcast on Monday, May 11, 2026 at 8:30am ET to discuss interim clinical data from the first three patients treated in its U.S. trial of Alpha DaRT for patients with recurrent glioblastoma (GBM), also known as the REGAIN (Recurrent Glioblastoma Alpha-DaRT Intratumoral Therapy) trial.","length":547,"tagName":"p"},{"type":"text","content":"Conference Call and Webcast Details","length":35,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Date: Monday, May 11, 2026","length":26,"tagName":"p"}]},{"val":[{"type":"text","content":"Time: 8:30am ET","length":15,"tagName":"p"}]},{"val":[{"type":"text","content":"Web Access: https://alpha-tau-interim-results-conference-call.open-exchange.net/","length":80,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":121,"olType":false},{"type":"text","content":"An archived webcast will be available following the event.","length":58,"tagName":"p"},{"type":"text","content":"About the REGAIN Study","length":22,"tagName":"p"},{"type":"text","content":"The clinical trial is expected to enroll up to ten U.S. patients with recurrent glioblastoma not amenable for surgical resection who have undergone a prior course of central nervous system radiation. The primary objective of the study is to evaluate the feasibility and safety of the treatment, following the Company’s promising ...